NATIONAL SAFETY COUNCIL CONGRESS & EXPO COMING TO HOUSTON, TX BREEZER MOBILE COOLING TO PARTICIPATE

National Safety Council (NSC) Congress & Expo will be held in Houston, TX this year. With over 14,000 safety professionals in attendance, it’s hailed as the largest event for the safety industry. The NSC’s mission is to eliminate preventable deaths at work, at home, and in the community through education and advocacy. With our dedication to keeping everyone safe and productive in extreme heat environments, we are excited to join the event as an exhibitor.

Attendees from safety, health, and environmental professions will be attending from 71 countries. This event is an opportunity to share new, innovative ideas around safety, focusing on what successful safety programs look like and how to execute them while keeping costs in check.

We’ll be there in booth #3846 with our Power Breezer and O2 portable cooling solutions. Our equipment allows for cooler spaces inside and outside. We will be sharing important information with the safety community about the dangers of heat illness and steps for prevention. With our cooling solutions, the benefits are immediate. Cooler employees make fewer mistakes and sustain productivity levels. Keeping workers safe and comfortable is a win for all.

That’s also what Jerry Condon, VP of Commercial Business Development observes and he comments “We have seen great ROI for companies in many different industries with our mobile cooling solutions. Our evaporative air coolers reduce mistakes, increase productivity, create a safe work environment and keep staff happy. At NSC, we’re going to share how our temperature control solutions make this possible.”

We look forward to meeting attendees from all over the globe and helping them achieve safer workspaces.

Be sure to stop by and visit us at booth #3846!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More